Chief Executive Officer, Extruded Pharmaceuticals
Andrew is currently Chief Executive Officer at Extruded Pharmaceuticals, a plaƞorm drug delivery technology company. The Company’s lead products are for the treatment of brain tumour, pancreatic and prostate cancers.
Andrew has over 30 years of commercial experience in the Diagnostics and Life Sciences industry. His previous roles include Chief Commercial Officer at Novel Technologies Holdings
Ltd. (NTH), Chief Executive Officer and founder of EKF Molecular Diagnostics and a nonexecutive director for Arcis Biotechnology.
Prior to EKF, Andrew joined QIAGEN as Senior Director, Personalised Healthcare following the acquisition of the pioneering personalised healthcare company, DxS Ltd in 2009 where he was Commercial Director. His early career included roles at Amersham Biosciences (now GE Healthcare) and in pre-clinical research at SmithKlineBeecham (now GlaxoSmithKline).